Epigral Limited
Epigral Limited Fundamental Analysis
Epigral Limited (EPIGRAL.NS) shows strong financial fundamentals with a PE ratio of 11.83, profit margin of 13.97%, and ROE of 18.49%. The company generates $24.2B in annual revenue with strong year-over-year growth of 34.65%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 73.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze EPIGRAL.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentEPIGRAL.NS demonstrates superior asset utilization.
Valuation Score
ExcellentEPIGRAL.NS trades at attractive valuation levels.
Growth Score
ExcellentEPIGRAL.NS delivers strong and consistent growth momentum.
Financial Health Score
ExcellentEPIGRAL.NS maintains a strong and stable balance sheet.
Profitability Score
WeakEPIGRAL.NS struggles to sustain strong margins.
Key Financial Metrics
Is EPIGRAL.NS Expensive or Cheap?
P/E Ratio
EPIGRAL.NS trades at 11.83 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, EPIGRAL.NS's PEG of -0.73 indicates potential undervaluation.
Price to Book
The market values Epigral Limited at 1.90 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 5.92 times EBITDA. This is generally considered low.
How Well Does EPIGRAL.NS Make Money?
Net Profit Margin
For every $100 in sales, Epigral Limited keeps $13.97 as profit after all expenses.
Operating Margin
Core operations generate 20.75 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $18.49 in profit for every $100 of shareholder equity.
ROA
Epigral Limited generates $10.44 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Epigral Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Epigral Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
EPIGRAL.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.83
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.73
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.90
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.65
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.26
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.31
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.18
vs 25 benchmark
ROA
Return on assets percentage
0.10
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How EPIGRAL.NS Stacks Against Its Sector Peers
| Metric | EPIGRAL.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.83 | 27.18 | Better (Cheaper) |
| ROE | 18.49% | 860.00% | Weak |
| Net Margin | 13.97% | -121084.00% (disorted) | Strong |
| Debt/Equity | 0.26 | 0.41 | Strong (Low Leverage) |
| Current Ratio | 1.31 | 4.81 | Neutral |
| ROA | 10.44% | -7173.00% (disorted) | Strong |
EPIGRAL.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Epigral Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
311.11%
Industry Style: Cyclical, Commodity, Value
High GrowthEPS CAGR
214.16%
Industry Style: Cyclical, Commodity, Value
High GrowthFCF CAGR
163.21%
Industry Style: Cyclical, Commodity, Value
High Growth